TY - JOUR
T1 - Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds
AU - Iwamoto, Taro
AU - Dorschner, Jessica
AU - Jolly, Meenakshi
AU - Huang, Xiangyang
AU - Niewold, Timothy B.
N1 - Funding Information:
Funding NIH grants (AR060861, AR057781, AR065964, AI071651), the Mayo Clinic Foundation, the Lupus Research Alliance and the Colton Center for Autoimmunity to TBN. National Natural Science Fund of China (No. 81072477)
Funding Information:
Competing interests TBN has received research grants from Janssen and EMD
Publisher Copyright:
© 2018 Article author(s).
PY - 2018
Y1 - 2018
N2 - Objective: The type I interferon pathway is activated in many patients with systemic lupus erythematosus (SLE), and anti-double-stranded DNA (dsDNA) and anti-RNA binding protein autoantibodies are correlated with high interferon-α (IFNα) activity. We studied whether antiphospholipid (APL) antibodies, which should not stimulate Toll-like receptors, are also associated with high levels of IFNα activity. Methods: Serum IFNα activity was measured in patients with SLE using the WISH cell bioassay. IgG APL, anti-RBP and anti-dsDNA antibodies were measured in the clinical laboratory, and standard clinical cut-offs were used to define the positive results. Results: High IFNα activity was associated with anti-RBP and anti-dsDNA antibodies in all three ancestral backgrounds. Strikingly, African-American subjects with a positive APL antibody test had higher IFNα activity than those without IgG APL antibodies. This was not shared with other ancestral backgrounds. This finding was independent of other autoantibody profiles, and clinical features did not differ between IgG APL antibody positive versus negative African-American patients. Conclusion: The difference in association between IFNα activity and IgG APL status between ancestral backgrounds supports differences in molecular pathogenesis. This may suggest B cell hyperactivity in the setting of type I IFN in African-Americans and could suggest ways to individualise therapy.
AB - Objective: The type I interferon pathway is activated in many patients with systemic lupus erythematosus (SLE), and anti-double-stranded DNA (dsDNA) and anti-RNA binding protein autoantibodies are correlated with high interferon-α (IFNα) activity. We studied whether antiphospholipid (APL) antibodies, which should not stimulate Toll-like receptors, are also associated with high levels of IFNα activity. Methods: Serum IFNα activity was measured in patients with SLE using the WISH cell bioassay. IgG APL, anti-RBP and anti-dsDNA antibodies were measured in the clinical laboratory, and standard clinical cut-offs were used to define the positive results. Results: High IFNα activity was associated with anti-RBP and anti-dsDNA antibodies in all three ancestral backgrounds. Strikingly, African-American subjects with a positive APL antibody test had higher IFNα activity than those without IgG APL antibodies. This was not shared with other ancestral backgrounds. This finding was independent of other autoantibody profiles, and clinical features did not differ between IgG APL antibody positive versus negative African-American patients. Conclusion: The difference in association between IFNα activity and IgG APL status between ancestral backgrounds supports differences in molecular pathogenesis. This may suggest B cell hyperactivity in the setting of type I IFN in African-Americans and could suggest ways to individualise therapy.
KW - antiphospholipid antibodies
KW - cytokines
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85048089207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048089207&partnerID=8YFLogxK
U2 - 10.1136/lupus-2017-000246
DO - 10.1136/lupus-2017-000246
M3 - Article
AN - SCOPUS:85048089207
SN - 2053-8790
VL - 5
JO - Lupus Science and Medicine
JF - Lupus Science and Medicine
IS - 1
M1 - e000246
ER -